XNAS
INMD
Market cap1.01bUSD
Apr 08, Last price
14.48USD
1D
-5.97%
1Q
-9.56%
IPO
106.56%
Name
Inmode Ltd
Chart & Performance
P/E
5.56
P/S
2.55
EPS
2.61
Div Yield, %
—
Shrs. gr., 5y
1.15%
Rev. gr., 5y
20.35%
Revenues
395m
-19.76%
Net income
181m
-8.41%
CFO
133m
-24.97%
Earnings
Apr 30, 2025
Profile
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | 394,818 -19.76% | 492,048 8.32% | 454,271 27.05% | ||||||
Cost of revenue | 282,287 | 296,388 | 256,417 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 112,531 | 195,660 | 197,854 | ||||||
NOPBT Margin | 28.50% | 39.76% | 43.55% | ||||||
Operating Taxes | (37,806) | 19,348 | 39,946 | ||||||
Tax Rate | 9.89% | 20.19% | |||||||
NOPAT | 150,337 | 176,312 | 157,908 | ||||||
Net income | 181,275 -8.41% | 197,919 22.54% | 161,520 -2.09% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (285,385) | 5,504 | (41,085) | ||||||
BB yield | 21.20% | -0.29% | 1.35% | ||||||
| Debt | |||||||||
Debt current | 2,511 | 2,404 | 1,453 | ||||||
Long-term debt | 13,133 | 15,630 | 7,018 | ||||||
Deferred revenue | 3,336 | 3,766 | 3,959 | ||||||
Other long-term liabilities | 3,356 | 1,399 | 303 | ||||||
Net debt | (581,528) | (724,271) | (539,512) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 132,664 | 176,826 | 181,578 | ||||||
CAPEX | (669) | (705) | (1,575) | ||||||
Cash from investing activities | 162,206 | (136,064) | (109,474) | ||||||
Cash from financing activities | (282,771) | 5,504 | (41,085) | ||||||
FCF | 143,701 | 142,939 | 145,777 | ||||||
| Balance | |||||||||
Cash | 596,472 | 741,605 | 547,383 | ||||||
Long term investments | 700 | 700 | 600 | ||||||
Excess cash | 577,431 | 717,703 | 525,269 | ||||||
Stockholders' equity | 874,610 | 691,992 | 488,255 | ||||||
Invested Capital | 140,896 | 109,562 | 56,346 | ||||||
ROIC | 120.05% | 212.54% | 210.40% | ||||||
ROCE | 15.67% | 24.41% | 36.33% | ||||||
| EV | |||||||||
Common stock shares outstanding | 80,597 | 85,954 | 85,404 | ||||||
Price | 16.70 -24.91% | 22.24 -37.70% | 35.70 -49.42% | ||||||
Market cap | 1,345,970 -29.59% | 1,911,608 -37.30% | 3,048,913 -49.78% | ||||||
EV | 764,442 | 1,187,337 | 2,509,401 | ||||||
EBITDA | 113,259 | 196,283 | 198,534 | ||||||
EV/EBITDA | 6.75 | 6.05 | 12.64 | ||||||
Interest | 3,612 | ||||||||
Interest/NOPBT | 1.83% | ||||||||